Compare TG Therapeutics Inc (TGTX) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Xcel Energy Inc — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Xcel Energy Inc trades at $73.78 (market cap $45.82B). The key difference: Xcel Energy Inc is far larger — about 5.6× TG Therapeutics Inc's market cap, and Xcel Energy Inc pays a 3.23% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Xcel Energy Inc for 61 Days on average.
| TGTX | XEL | |
|---|---|---|
Market Cap | $8.16B | $45.82B |
Volume | 1,735,121 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $59.06 | $83.91 |
52-Week Low | $26.94 | $69.39 |
Typical Hold Time | 16 Days | 61 Days |
Enterprise Value | $8.37B | $84.14B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Xcel Energy (XEL) trades at $73.36, up 1.3% with bullish technical signals and strong institutional support. The stock shows solid fundamentals with $14.67B revenue, 15.28% net margin, and consistent earnings beats. Recent news highlights growth from data center power demand and a $60B capital investment plan. Technical indicators show bullish momentum with support at $72-73 and resistance at $74-75 levels.
XEL presents a compelling investment case with analyst consensus target of $90.83 (24% upside) and 63% buy ratings. Key opportunities include infrastructure expansion and rising power demand, while risks involve wildfire liabilities and high capital expenditure. The stock's valuation at 20.1 P/E appears reasonable given growth prospects and dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
